Medically reviewed by Sohaib Imtiaz, MD Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat ...

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day. Subscribe for FREE Patients exploring weight-loss management strategies may elect ...

Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent ...

Compounding of another big-selling GLP-1 drug – Eli Lilly's tirzepatide – was blocked in December after that ... from compounded semaglutide to the FDA-approved brands before changing its ...

Researchers saw no benefits in terms of weight loss when patients received neoadjuvant semaglutide before metabolic and bariatric surgery.

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the ...

Patients receiving preoperative semaglutide versus controls had similar median hemoglobin A1c levels before MBS and one year after MBS. Furthermore, both cohorts had a similar number of patients ...